Denied Hizentra? You Still Have Options.
Hizentra (subcutaneous immunoglobulin) is a specialty medication used to treat primary immunodeficiency (PI) and CIDP, and insurance denials are more common than you might think. Insurers frequently require prior authorization before covering Hizentra, and many plans insist you try an alternative immunoglobulin product first — a process called step therapy. Some formularies exclude Hizentra entirely, even when your doctor has specifically prescribed it for your situation.
Option 1: Appeal Your Denial
You have the right to appeal any insurance denial, and a strong medical necessity letter from your doctor can make a real difference. Appeals for Hizentra often succeed when they include documentation of why the specific delivery method (subcutaneous vs. intravenous) matters for your health and your quality of life. Ellen can help you draft your appeal letter.
Option 2: Explore Clinical Trials
Clinical trials studying subcutaneous immunoglobulin therapies — including those in the same drug class as Hizentra — are ongoing for primary immunodeficiency and CIDP. These studies may provide access to treatment at no cost while contributing to research that helps others facing the same denial. You can search active trials at ClinicalTrials.gov using terms like "subcutaneous immunoglobulin" or "SCIG."
Option 3: Patient Assistance Programs
CSL Behring, the manufacturer of Hizentra, offers a patient assistance program called CSL Behring Assist that may help cover costs if you meet income requirements. The Immune Deficiency Foundation (primaryimmune.org) also maintains resources and financial assistance connections for people living with primary immunodeficiency.
For a complete guide to Hizentra financial assistance — including copay cards, free drug programs, and independent foundations — see our financial assistance page for Hizentra.
Ellen can help you figure out your next step. Start with Ellen →
Frequently Asked Questions
Why was Hizentra denied?
The most common reasons Hizentra gets denied include missing or incomplete prior authorization paperwork, step therapy requirements (your insurer may want you to try a different immunoglobulin product first), or formulary exclusion (Hizentra isn't on your plan's covered drug list). Sometimes it comes down to the route of administration — some plans cover intravenous immunoglobulin (IVIG) but not the subcutaneous form. Your denial letter should list the specific reason, and that reason shapes the best path forward for your appeal.
Can I get Hizentra through a clinical trial?
Possibly, though clinical trials don't always study the exact same medication that was denied. Trials in the immunoglobulin space may study Hizentra directly, a similar subcutaneous formulation, or a next-generation therapy in the same class. What they often have in common is that approved participants receive the study medication at no charge. Talk to your doctor about whether a trial might be appropriate for your situation, and search ClinicalTrials.gov for current options.
How long does a Hizentra appeal take?
Timelines vary based on the type of appeal. A standard internal appeal typically takes up to 30 days for non-urgent cases, or 72 hours for urgent medical situations. If your internal appeal is denied, you can request an external review by an independent organization — that process usually takes another 45 days or fewer. Your denial letter will include the specific deadlines that apply to your plan. Talk to your doctor before making any decisions about your treatment.